TLDR 5 mg/mL of triamcinolone acetonide is most effective for hair regrowth with fewer side effects.
This systematic review and meta-analysis evaluated the efficacy and tolerability of different concentrations of intralesional triamcinolone acetonide for treating focal alopecia areata. Seven studies with 543 participants were included. Hair regrowth rates were 62.3% for concentrations less than 5 mg/mL, 80.9% for 5 mg/mL, and 76.4% for 10 mg/mL. Skin atrophy occurred in 3.33% of subjects treated with 5 mg/mL and 20% with 10 mg/mL. The analysis suggested that 5 mg/mL offered the best risk-benefit ratio, but further randomized studies were recommended to determine the lowest effective concentration.
Cited in this study
2 / 2 results
128 citations
,
July 2016 in “British Journal of Dermatology” Alopecia areata significantly lowers the quality of life, especially in emotional and mental health aspects.
391 citations
,
February 2010 in “Journal of The American Academy of Dermatology” Half of people with Alopecia Areata may see hair regrowth within a year without treatment, but recovery is unpredictable.
148 citations
,
March 2019 in “Journal of autoimmunity” Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
4 citations
,
November 2018 in “JAAD case reports” Alopecia areata can sometimes appear as a straight line of hair loss instead of round patches.
May 2018 in “Journal of cosmetology & trichology” Combining platelet-rich plasma therapy with prostaglandin-F eye drops can significantly regrow hair in alopecia universalis.
110 citations
,
December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Alopecia areata is a genetic and immune-related hair loss condition that is often associated with other autoimmune diseases and does not typically cause permanent damage to hair follicles.
